BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 29409778)

  • 1. Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study).
    Zaanan A; Samalin E; Aparicio T; Bouche O; Laurent-Puig P; Manfredi S; Michel P; Monterymard C; Moreau M; Rougier P; Tougeron D; Taieb J; Louvet C
    Dig Liver Dis; 2018 Apr; 50(4):408-410. PubMed ID: 29409778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Anter AH; Abdel-Latif RM
    Med Oncol; 2013 Mar; 30(1):451. PubMed ID: 23307258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E
    Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
    Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
    Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
    Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G; Jauhri M; Negi A; Aggarwal S
    Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Ochenduszko S; Puskulluoglu M; Konopka K; Fijorek K; Urbanczyk K; Budzynski A; Matlok M; Lazar A; Sinczak-Kuta A; Pedziwiatr M; Krzemieniecki K
    Med Oncol; 2015 Oct; 32(10):242. PubMed ID: 26354521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
    Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P
    Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
    Pernot S; Mitry E; Samalin E; Dahan L; Dalban C; Ychou M; Seitz JF; Turki H; Mazard T; Zaanan A; Lepère C; Vaillant JN; Landi B; Rougier P; Taieb J
    Gastric Cancer; 2014 Apr; 17(2):341-7. PubMed ID: 23739764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.
    Malka D; François E; Penault-Llorca F; Castan F; Bouché O; Bennouna J; Ghiringhelli F; de la Fouchardière C; Borg C; Samalin E; Bachet JB; Raoul JL; Miglianico L; Bengrine-Lefèvre L; Dahan L; Lecaille C; Aparicio T; Stanbury T; Perrier H; Cayre A; Laurent-Puig P; Gourgou S; Emile JF; Taïeb J
    Eur J Cancer; 2019 Jul; 115():97-106. PubMed ID: 31129386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
    J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
    BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
    Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
    Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
    Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
    Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.